• Cancer screening and breast cancer family history in Spanish-speaking Hispanic/Latina women in California.
    • Tamayo LI, Perez F, Perez A, Hernandez M, Martinez A, Huang X, Zavala V, Ziv E, Neuhausen S, Carvajal-Carmona LG, Duron Y, Fejerman L.
    • Front Oncol. 2022 Sep 28;12:940162. doi: 10.3389/fonc.2022.940162.
  • LitAlert ~~ GeneLit.com

    • Genetic testing for patients at risk of hereditary breast and ovarian cancer.
    • DeTroye A, Gabbett K, Yi C, Judice M, Luu V, Nelson B, Gregory T.
    • JAAPA. 2022 Oct 1;35(10):48-52. doi: 10.1097/01.JAA.0000873796.81961.da.
    • Using Social Media to Facilitate Communication About Women's Testing: Tool Validation Study.
    • Coffin T, Bowen D, Lu K, Swisher EM, Rayes N, Norquist B, Blank SV, Levine DA, Bakkum-Gamez JN, Fleming GF, I Olopade O, Romero I, D'Andrea A, Nebgen DR, Peterson C, Munsell MF, Gavin K, Crase J, Polinsky D, Lechner R.
    • JMIR Form Res. 2022 Sep 26;6(9):e35035. doi: 10.2196/35035.

    Identifier: NCT02993068: Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible). (ClinicalTrials.gov)

    • Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants.
    • Ohneda K, Hamanaka Y, Kawame H, Fuse N, Nagami F, Suzuki Y, Yamaguchi-Kabata Y, Shimada M, Masamune A, Aoki Y, Ishida T, Yamamoto M.
    • Breast Cancer. 2022 Sep 26. doi: 10.1007/s12282-022-01404-7. Epub ahead of print.
    • Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing.
    • Bokkers K, Bleiker EMA, Hoogendam JP, Velthuizen ME, Schreuder HWR, Gerestein CG, Lange JG, Louwers JA, Koudijs MJ, Ausems MGEM, Zweemer RP.
    • Hered Cancer Clin Pract. 2022 Sep 8;20(1):33. doi: 10.1186/s13053-022-00238-w.
    • Polygenic risk scores and risk-stratified breast cancer screening: Familiarity and perspectives of health care professionals.
    • Lapointe J, Buron AC, Mbuya-Bienge C, Dorval M, Pashayan N, Brooks JD, Walker MJ, Chiquette J, Eloy L, Blackmore K, Turgeon A, Lambert-Côté L, Leclerc L, Dalpé G, Joly Y, Knoppers BM, Chiarelli AMSimard J, Nabi H.
    • Genet Med. 2022 Sep 3:S1098-3600(22)00892-9. doi: 10.1016/j.gim.2022.08.001. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Experience with a nurse-driven genetic counseling pathway of Italian women with uninformative BRCA test result.
    • Blondeaux E, Lambertini M, Buzzatti G, Bruzzone C, Baraga M, Pisani R, Del Mastro L, Pronzato P, Varesco L, Bonelli L.
    • J Genet Couns. 2022 Aug 29. doi: 10.1002/jgc4.1630. Epub ahead of print.
    • Integrating hereditary breast and ovarian cancer genetic counselling and testing into mainstream clinical practice: Legal and ethical challenges.
    • Charron M, Kaiser B, Dauge A, Gallois H, Lapointe J, Dorval M, Nabi H, Joly Y.
    • Crit Rev Oncol Hematol. 2022 Aug 25:103797. doi: 10.1016/j.critrevonc.2022.103797. Epub ahead of print.
    • Review
    • Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
    • Bokkers K, Frederix GWJ, Velthuizen ME, van der Aa M, Gerestein CG, van Dorst EBL, Lange JG, Louwers JA, Koole W, Zweemer RP, Ausems MGEM.
    • Gynecol Oncol. 2022 Aug 28:S0090-8258(22)00550-9. doi: 10.1016/j.ygyno.2022.08.011. Epub ahead of print.